| Andrea Murray, PHARM D | |
|
1718 Soquel Ave, Santa Cruz, CA 95062-1306 | |
| (831) 425-3911 | |
| (831) 425-2074 |
| Full Name | Andrea Murray |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1718 Soquel Ave, Santa Cruz, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134405210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 61126 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrea Murray, PHARM D 1718 Soquel Ave, Santa Cruz, CA 95062-1306 Ph: (831) 425-3911 | Andrea Murray, PHARM D 1718 Soquel Ave, Santa Cruz, CA 95062-1306 Ph: (831) 425-3911 |
News Archive
Dynatronics Corporation, a manufacturer and marketer of rehabilitation and physical therapy products, announced today that it has completed its $4,025,000 private placement financing led by affiliates of Prettybrook Partners LLC (collectively, "Prettybrook"), a strategic private equity investor focused on the healthcare industry.
MedPage Today: "The public can now review data on the quality of outpatient care provided by individual hospitals at the Centers for Medicare and Medicaid Services' Hospital Compare website. The site previously contained only data on inpatient care quality. All the data are derived from records of Medicare patients treated at more than 3,600 hospitals nationwide."
Abbot and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.
Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into an agreement with Amdipharm for the licensing and commercialization of its proprietary products throughout Asia. Under this agreement, Invida will leverage its full suite of capabilities to bring Amdipharm's products to market, from regulatory approval and licensing, through packaging and supply chain optimization, to commercialization, sales, and marketing.
Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.
› Verified 2 days ago
Dr. Nhu Quynh T Doan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2900 Chanticleer Ave, Santa Cruz, CA 95065 Phone: 831-477-2240 | |
Linh Nguyen, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 Mission St, Santa Cruz, CA 95060 Phone: 831-457-2481 | |
Cindy Jeehye Park, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 901 Soquel Ave, Santa Cruz, CA 95062 Phone: 831-426-4303 | |
Mr. John Lee Lau, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 117 Morrissey Blvd, Santa Cruz, CA 95062 Phone: 831-426-8911 | |
Kathleen Elmore, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 117 Morrissey Blvd, Santa Cruz, CA 95062 Phone: 831-426-8911 | |
Carrie Cai, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2203 Mission St, Santa Cruz, CA 95060 Phone: 831-420-0785 |